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Abstract 
Purpose: To optimize the preparation of insulin-chitosan nanoparticles (ICNS) using response surface 
methodology (RSM). 
Methods: ICNS were formulated through ionic cross linking method. The effects of the ratio between 
insulin and chitosan, pH of the medium and rotation speed on insulin encapsulation efficiency (EE) were 
investigated. Box-Behnken experimental design coupled with response surface method was employed 
to optimize formulation. Properties such as particle shape, size, zeta potential and release behavior 
were analyzed.  
Results: The best formulation was produced under the following conditions: the ratio between insulin 
and chitosan was 0.08, pH 3.0, and rotation speed 187.4 rpm. Verifying experiments were established 
under the optimal conditions and EE was 93.1 %. Nanoparticles showed fine degree of sphericity and 
homogenous distribution of particle size. The particle size of nanoparticles was between 91.3 ± 7.9 and 
220.2 ± 9.5 nm and the average zeta potential was 14.4 ± 2.9 mv. More than 16.8 % of total drug was 
released rapidly in the first 1 h. Thereafter, the insulin trapped in ICNS was released into the medium 
slowly and > 93.0 % was released completely within 24 h. Ritger-Peppas model was the best-fit drug 
release from all the formulations. The diffusion exponent (n) indicates that drug release pattern was 
non-Fickian diffusion. 
Conclusion: Response surface method was a useful tool to predict the optimal formulation. ICNS 
showed excellent characteristics of homogenous particle size distribution, good spherical property, 
positive zeta potential and longer drug delivery. It could be a promising carrier for the oral administration 
of insulin. 
Keywords: Nanoparticles, Response surface methodology, Insulim release, Encapsulation efficiency, 
Zeta potential, Ritger-Peppas model, Box-Behnken design. 
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Research on insulin in the management of 
diabetes mellitus and its preparations is still 
attracting increasing attention. Researchers tend 
to design a variety of insulin formulations based 
on drug delivery theory as a foundation and after 
a thorough research on physico-chemical 
properties in vitro and in vivo pharmaco-
dynamics. Insulin formulations for oral delivery 
are emulsions [1], liposomes [2], microspheres 
[3] and nanoparticles [4]. Nanoparticles, as a 
drug delivery system, have become an excellent 
oral insulin delivery carrier [5]. Research shows 
that nanoparticles produced intestinal uptake in 
M cells and transport across membrane in the 
intestinal villi positions. When the small intestinal 
epithelial cells and Cells which had similar 
functions with M cells were co-cultured in vitro, 
transport velocity of polystyrene particles with 
200 and 500 nm were increased 200-fold [6]. 
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Chitosan (CS) as the only alkalescent 
polysaccharide in nature has a good 
biocompatibility, biodegradability, adhesion and 
non-toxicity and has been widely used in medical 
and pharmaceutical field [7-9]. It has been 
demonstrated that the positively charged 
chitosan nanoparticles had strong electrostatic 
interaction with the negatively charged mucin 
glycosylation, leading to strong mucosal 
adhesion. This interaction is responsible for 
prompting the contact between nanoparticles and 
epithelial cells and increasing uptake of particles 
in aggregate lymphoid nodule [10-11]. The 
objective of this study was to prepare insulin-
chitosan nanoparticles (ICNS) using ionic cross-
linking method. Response surface method was 
applied to optimize the formulation and analyze 
the influence of variables on insulin 
encapsulation efficiency. Some properties of 
particles such as shape, size, zeta potential and 






Chitosan (CS, 400kDa) was obtained from Haixin 
Biological Product Co., Ltd, China, while insulin 
(27.5IU.mg-1) was purchased from Jiangsu 
Wangbang Bio-Technology Co., Ltd, China. 
Trimeric sodium phosphate (TPP) and acetic 
acid were obtained from Sigma Chemicals, St 
Louis, USA. All other chemicals purchased were 





The ratio between insulin and chitosan (A), pH of 
medium (B) and rotation speed (C) were the 3 
main effective factors and drug encapsulation 
efficiency as response surface experimental 
factors were selected to carry out the 
experiments. Range of the ratio between insulin 
and chitosan (g/g) was 0.05~ 0.15, pH of 
medium was 3.0～6.0, rotation speed was 100～
300 rpm. Box-Behnken central composite design 
principle was adopted to optimize experimental 
design and the data analyzed using Design-
Expert®, version 8.0.6.1  (Stat-Ease Inc, USA) to 
generate a Box-Behnken matrix design as shown 
in Table 1. Out of a total test point of 17 
obtained, 12 were factorial points while 5 were 
zero points to evaluate error. 
 
Preparation of ICNS 
 
CS (50 mg) was dissolved in 1% (v/v) acetic acid 
solution, stirring with a magnetic stirrer and 
swelling over night. Saturated NaOH solution 
was used to adjust the pH of the medium to the 
exact pH used. NaOH (0.01 mol/L) solution 
containing insulin was added with a dropper at 2 
ml/min into the chitosan solution and stirring 
continued for 2 h. TPP reserve liquid (0.5 mg/mL) 
was prepared and filtered through 0.45 m filter    
 
Table 1: Box-Behnken matrix design scheme and response values 
 
Fomulation  
code A(g/g) B C/rpm 
Y EE(%) 
F1 0.10 4.50 200.00 88.0±3.4 
F2 0.10 4.50 200.00 87.6±5.6 
F3 0.10 4.50 200.00 86.9±4.1 
F4 0.10 6.00 300.00 86.5±3.9 
F5 0.10 4.50 200.00 86.8±6.1 
F6 0.15 4.50 300.00 79.8±5.2 
F7 0.15 4.50 100.00 64.7±3.5 
F8 0.05 3.00 200.00 91.5±4.9 
F9 0.05 4.50 300.00 82.5±4.7 
F10 0.05 6.00 200.00 81.9±3.9 
F11 0.15 3.00 200.00 81.2±5.1 
F12 0.15 6.00 200.00 69.9±3.6 
F13 0.10 3.00 100.00 87.8±4.2 
F14 0.10 6.00 100.00 73.4±3.1 
F15 0.10 3.00 300.00 85.6±5.9 
F16 0.05 4.50 100.00 78.7±4.4 
F17 0.10 4.50 200.00 88.3±5.5 
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(Jiuding Inc, China). ICNS were prepared by 
dropping 3 ml of TPP reserve liquid quickly into 
the system at 40 ºC and continuously stirred at 
certain speed ranging from 100 to 300 rpm for 1 
h until the mixture turned creamy. ICNS collected 
was washed 3 times with deionized water and 
centrifuged at 16000 rpm for 20 min. The 
particles were freeze-dreid using vacuum freeze 
drier (FD-1, Boyikang, China) to obtain the 
powders. 
 
Characterization of ICNS 
 
Scanning electron microscopy (S-4800, Hitachi, 
Japan) was used to observe the morphology of 
ICNS. Particle size and zeta potential were 
determined using a Zetasizer (Nano ZS90, 
Malvern, UK). 
 
Determination of drug encapsulation 
efficiency 
 
Dried ICNS (5 mg) was dispersed in 10 ml of 
0.01 mol/L HCl solution.Ultrasonic extraction was 
performed for 15 min at 4 oC . The product 
obtained was centrifuged at 16000 rpm for 30 
min and the supernatant was collected and 
filtered through a 0.22 mm millipore filter. The 
absorbance of the filtrate was taken at 276 nm 
using a UV/Visible spectrophotometer (model 
1601, Shimadzu, Japan) to determine the 
amount of insulin trapped in the ICNS. The 
encapsulation efficiency (EE, %) was calculated 
using Eq 1. 
 
EE (%) = {(Si – Sf)/Si}100 ……………… (1) 
 
where Si is the initially added insulin and Sf is the 
free insulin in the supernatant, 
 
Investigation of drug release behavior 
 
The in vitro release profile of insulin from 
nanoparticles was investigated by determining 
the residual amount of insulin present in the 
nanoparticles. Several amount (2 mg) of the 
same freeze dried ICNS were suspended in 
tubes with caps filled with 5ml phosphate buffer 
(pH 7.4) at 37 oC and shaken horizontally at 50 
min-1 by using an orbital shaker bath (SHA-C, 
Kaihang, China). At preselected time intervals, 
three of tubes were withdrawn and centrifuged at 
16000 rpm for 30 min and the precipitated ICNS 
was collected and washed 3 times with deionized 
water. The amount of residual insulin in 
nanoparticles was analyzed at 276 nm by using 
the same method as described in the section of 
determination of drug encapsulation efficiency. 
The cumulative amount of insulin (AR) released 
from ICNS at different time was calculated using 
Eq 2.  
 
AR (%) = {(St – Sr)/St}100 ……………… (1) 
 
where St is the initially trapped insulin and Sr is 




One-way ANOVA was applied to determine 
significant difference between various values. 




Response surface ethodology (RSM) 
 
The encapsulation efficiency of ICNS (Y) ranged 
from 64.7±3.5 to 91.5±4.9 %. RSM results for 
response Y (% encapsulation efficiency) are 
given in Table 1. The resultant equation for 
response Y is shown in Eq 3. 
 
Y = +87.52-4.87A - 4.30B+3.72 C-
43AB+2.83AC+3.82BC-6.65A2+0.25B2-4.45C2 …….. (3) 
 
The result of regression variance analysis and 
significance test on the model was investigated. 
F value is 31.24 and the p value < 0.0001, which 
demontrates that the model is highly significant. 
Model determination coefficient value was 
0.9445,  which showed that there was linear 
relationship between the equation dependent 
variables and all independent variables. The 
related influence of three factors classified in 
response value from high to low was the ratio 
between insulin and chitosan (A), pH of medium 
(B) and rotation speed (C). Factors that affected 
the response value remarkably were A, B, C, AC, 
BC, A2, C2 and no simple linear relationship was 
established between the response values and 
factors. Three factors had a strong interaction on 
the response value. 
 
The regression optimization response surface 
plot is shown in Figure 1. The ratio between 
insulin and chitosan (A) can affect EE. As shown 
in Figure 1-I, EE value was increased with the 
increase of the ratio. When the ratio between 
insulin and chitosan (A) was 0.08 g/g, maximum 
EE value was 92.82 %. After that, EE value 
decreased with increase in the ratio. With the 




Response surface analysis 
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Figure 1: Effect of (I) insulin:chitosan ratio (A) and pH 
of medium (B); (II) insulin:chitosan ratio (A) and 
rotation speed (C); (III) pH of medium (B) and rotation 
speed (C) on encapsulation efficiency (EE) 
 
The regression optimization response surface 
plot is shown in Figure 1. The ratio between 
insulin and chitosan (A) can affect EE. As shown 
in Figure 1-I, EE value was increased with the 
increase of the ratio. When the ratio between 
insulin and chitosan (A) was 0.08 g/g, maximum 
EE value was 92.82 %. After that, EE value 
decreased with increase in the ratio. With the 
decrease of pH of medium (B), EE value was 
increased gradually. Flatness of surface 
suggested that interaction between factors A and 
B was weak. As shown in Figure 1 (II), as ratio 
and rotation speed (C) increased, EE value 
showed a curved surface. When the ratio was 
0.09 g/g and rotation speed was 232.46 rpm, 
maximum EE value obtained was 88.85 %. The 
curves displayed a steep slope, indicating that 
factors A and C had significant interaction (p < 
0.05). The interaction graph between pH of 
medium (B) and rotation speed (C) is shown in 
Figure 1 (III). Maximum EE (92.07 %) was 
obtained when pH and rotation speed were 3 and 
198.93 rpm, respectively. The sharp slope of the 
surface implies that the interaction between B 
and C was significant (p < 0.05). The optimal 
condition for formulation of ICNS was as follows: 
insulin/chitosan ratio 0.08, pH 3.0,and rotation 
speed 187.4 rpm. The highest encapsulation 
efficiency of 92.88% was obtained. Verifying 
experiments were established under the optimal 
conditions and EE was 93.10 % with low 
percentage bias (3.78%).  
 
Morphology of ICNS 
 
The size range of ICNS was between 91.28 ± 7.9 
and 220.2 ± 9.5 nm and the average zeta 
potential was 14.4 ± 2.9 mv. It can be seen from 
Figure 2 that ICNS showed good sphericity with 
good monodispersity and homogenous particle 
size distribution. 
 
Figure 3 shows that three ICNS formulations (F1, 
F8 and F17) prepared using the matrix design 
and the optimal formulation (Fof) exhibited good 
drug release behavior. More than 16.8% of total 
drug was released rapidly in the first 1 h. 
Thereafter, insulin trapped in ICNS was released 
into the medium slowly and > 93 % was released 
completely within 24 h. The in vitro release data 
were fitted into release kinetics models with the 
aid of using Origin Version 8.0 to determine the 
best-fit release model . 
 
The release kinetic data analysis and correlation 
coefficient ( R2) are shown in Table 2. The 
relationship between cumulative release rate and 
time was tested using Zero-order, First-order, 
Higuchi and Ritger-Peppas models. For all the 
foumulations, in vitro drug release was best fitted 
to Ritger-Peppas modelwhich showed the 
highest correlation coefficient ( R2). The 
diffusional exponent (n) in Ritger-Peppas model 
was greater than 0.45, which suggests that drug 
Zhao et al 
Trop J Pharm Res, January 2014;13 (1): 
 
7
release from ICNS was non-Fickian diffusion and 
therefore was influnced by drug diffusion and 







Figure 2: Morphology of ICNS (Note: A = particle 
distribution of ICNS, B = zeta potential distribution of 
ICNS, and C = SEM of ICNS) 
 



























Figure 3: Drug release of ICNS (Note: F1 = Δ, F8 = , 
Fof = , F17 = □) (n = 3) 
 








 R2     R2 R2 R2 n 
F1 0.9091 0.9788 0.9732 0.9794 0.6269 
F2 0.838 0.9716 0.9700 0.9806 0.4845 
Fof 0.9024 0.9718 0.9679 0.9819 0.5831 
F17 0.8871 0.9557 0.9574 0.9670 0.6350 
DISCUSSION 
 
Response surface method was a useful tool to 
predict formulation and was adopted to establish 
the function of relation between regression 
factors and experimental results, finding explicit 
functions, regression equation on factors and 
response value through the whole rigion. The 
highest response value and the optimal 
formulation were obtianed with good predition 
[13,14]. Using RSM, it is possible to optimize the 
formulation with optimum drug encapsulation 
efficiency，good sphericity and homogenous 
particle size distribution [15].  ICNS showed the 
rapid drug release during the initial period and 
more than 16.8% of total drug were released 
from ICNS within the first 1 h. This is perhaps 
due to the fact that free insulin was attached to 
the surface of ICNS or migrated toward the 
surface with evaporation of water during the 
freeze-drying process, leading to rapid dumping 
from ICNS at the initial stage. Drug release 
decreased after rapid release was completed. As 
the formation of a porous structure through the 
whole ICNS by continuous dissolution and 
erosion of chitosan continued, drug resistance to 
dissolution and diffusion reduced, and thus drug 




ICNS prepared showed excellent properties on 
morphology and also displayed a prolonged drug 
release within 24 h. It could be a promising 
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